Musculoskeletal and CNS coccidiomycosis in an individual with multiple sclerosis on fingolimod - A case report

被引：0
|
作者：
Denton, Jacob [1 ]
Ozgur, Hasan [2 ]
Sazegar, Pantea [1 ]
Galgiani, John [3 ]
Riaz, Talha [4 ]
机构：
[1] Univ Arizona, Coll Med, Tucson, AZ USA
[2] Univ Arizona, Diagnost Radiol, Coll Med, Tucson, AZ USA
[3] Univ Arizona, Coll Med, Valley Fever Ctr Excellence, Tucson, AZ USA
[4] Banner Univ, Dept Internal Med, Div Infect Dis, Med Ctr, Tucson, AZ USA
来源：
IDCASES | 2024年 / 37卷
关键词：
Fingolimod; Multiple sclerosis; Coccidioides; CNS fungal infections;
D O I：
10.1016/j.idcr.2024.e02021
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We report the case of a 56-year-old female with a past medical history of multiple sclerosis on disease-modifying therapy of fingolimod who presented with disseminated Coccidioides infection, initially of the ankles bilaterally before progressing to the central nervous system. CNS coccidiomycosis has thus far not been associated with any pharmacological therapy for multiple sclerosis. Clinicians should have a high degree of suspicion for Coccidioides infection in immunosuppressed patients living in endemic areas.
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Oxidative stress activity of fingolimod in multiple sclerosis
    Yevgi, Recep
    Demir, Recep
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2021, 202
  • [32] Melanoma during fingolimod treatment for multiple sclerosis
    Velter, C.
    Thomas, M.
    Cavalcanti, A.
    Bastien, M.
    Chochon, F.
    Lubetzki, C.
    Routier, E.
    Robert, C.
    EUROPEAN JOURNAL OF CANCER, 2019, 113 : 75 - 77
  • [33] FINGOLIMOD THERAPY IN MULTIPLE SCLEROSIS - THE ISSUE OF THE PATHOMECHANISM
    Tar Lilla
    Vecsei Laszlo
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2012, 65 (3-4): : 83 - 100
  • [34] Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis – a case report
    Martina Petruzzo
    Roberta Lanzillo
    Neurological Sciences, 2021, 42 : 37 - 39
  • [35] Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis
    Tanasescu, Radu
    Constantinescu, Cris S.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (04) : 621 - 630
  • [36] Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases
    Hakiki, Bahia
    Portaccio, Emilio
    Giannini, Marta
    Razzolini, Lorenzo
    Pasto, Luisa
    Amato, Maria Pia
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) : 1636 - 1639
  • [37] Efficacy of fingolimod after switching from interferon β-1a in an adolescent with multiple sclerosis: case report
    Amidei, Annalisa
    Siciliano, Gabriele
    Pasquali, Livia
    NEUROLOGICAL SCIENCES, 2021, 42 (SUPPL 1) : 5 - 7
  • [38] Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model
    Anthony, Daniel C.
    Sibson, Nicola R.
    Losey, Patrick
    Meier, Daniela Piani
    Leppert, David
    NEUROPHARMACOLOGY, 2014, 79 : 534 - 541
  • [39] Efficacy of fingolimod after switching from interferon β-1a in an adolescent with multiple sclerosis: case report
    Annalisa Amidei
    Gabriele Siciliano
    Livia Pasquali
    Neurological Sciences, 2021, 42 : 5 - 7
  • [40] Fingolimod: a novel oral immunomodulatory treatment for multiple sclerosis
    Javed, Adil
    Soliven, Betty
    FUTURE NEUROLOGY, 2011, 6 (03) : 315 - 325
12345